Adds small molecule inhibitors against targets Involved in epigenetic regulation
US biotechnology company Gilead Sciences, is to buy privately held EpiTherapeutics for US$65m in cash.
Denmark-based EpiTherapeutics develops cancer treatments, focusing on the enzymes involved in the regulation of transcription in cancer.
Norbert Bischofberger, Gilead’s EVP, Research and Development and Chief Scientific Office, said: 'Epigenetics is a promising area of research and the EpiTherapeutics team is a recognised scientific leader in this field.
'This therapeutic class represents a strategic fit with our existing research portfolio, including the potential for novel combination approaches.'
Martin Bonde, CEO of EpiTherapeutics, said: 'EpiTherapeutics has done groundbreaking work in a new therapeutic class of small molecule inhibitors with broad implications across various disease states.
'We are confident that with Gilead’s acquisition of the company, our discoveries will have the best chance to be developed into therapies that will benefit patients.'